Filing Details
- Accession Number:
- 0001209191-21-012038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-18 17:58:49
- Reporting Period:
- 2021-02-16
- Accepted Time:
- 2021-02-18 17:58:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1770787 | 10X Genomics Inc. | TXG | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1189140 | R John Stuelpnagel | C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Disposition | 2021-02-16 | 400 | $189.51 | 465,591 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 1,400 | $190.42 | 464,191 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 2,683 | $191.63 | 461,508 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 451 | $192.61 | 461,057 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 600 | $194.60 | 460,457 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 800 | $195.43 | 459,657 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 633 | $197.36 | 459,024 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 233 | $198.08 | 458,791 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2021-02-16 | 300 | $199.78 | 458,491 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- This transaction was executed in multiple trades at prices ranging from $188.99 to $189.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $190.05 to $190.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $191.11 to $192.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $192.18 to $192.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $194.15 to $195.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $195.24 to $195.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $196.86 to $197.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $197.89 to $198.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $199.46 to $200.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Billionaire Hedge Funds
